Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

J
Jackson, Aimee

Cancer Research UK Clinical Trials Unit, University of Birmingham
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Aimee Jackson
Favorite
Jackson, Nicola

Cancer Research UK Clinical Trials Unit, University of Birmingham
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Nicola Jackson
Favorite
Jacob, Allison

Adaptive Biotechnologies
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Allison Jacob
Favorite
Jacobson, Caron

Dana-Farber Cancer Institute
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Caron Jacobson
Favorite
Jaeger, Ulrich

Medical University of Vienna
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Ulrich Jaeger
Favorite
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Ulrich Jaeger
Favorite
Jaglowski, Samantha

The Ohio State University Comprehensive Cancer Center
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Samantha Jaglowski
Favorite
Jaimes-Delgadillo, Nydia

Wilmot Cancer Institute / University of Rochester Medical Center
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Nydia Jaimes-Delgadillo
Favorite
Jain, Nitin

University of Texas MD Anderson Cancer Center
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Nitin Jain
Favorite
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Nitin Jain
Favorite
Jaksic, Jelena

School of Medicine University of Zagreb
1130 - Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment
Jelena Jaksic
Favorite
Jaksic, Ozana

School of Medicine University of Zagreb
1019 - Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy
Ozana Jaksic
Favorite
Jaksic, Ozren

University Hospital Dubrava and Medical School, University of Zagreb
1019 - Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy
Ozren Jaksic
Favorite
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Ozren Jaksic
Favorite
1130 - Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment
Ozren Jaksic
Favorite
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Ozren Jaksic
Favorite
James, Dan

Polaris Biostatistics Ltd.
1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
Dan James
Favorite
Jamieson, Catriona

Division of Regenerative Medicine and Moores Cancer Center, University of California San Diego
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Catriona Jamieson
Favorite
Jannuru, Suman

AstraZeneca
1220 - Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials (RCTs)
Suman Jannuru
Favorite
Jara, Paola

Josep Carreras Leukaemia Research Institute
1104 - Non-Hematological Autoimmune Disorders are frequent in CLL, but are they clinically related? Data from a Single-center Real-Life Cohort
Paola Jara
Favorite
1117 - EVOLUTION IN THE FRONTLINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EXPERIENCE FROM ONE EUROPEAN CENTER
Paola Jara
Favorite
1129 - Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Paola Jara
Favorite
Jawaid, Dureshahwar

AbbVie
1143 - The Economic Benefits of Time Off Treatment: Real-World HRU, Costs, and Subsequent Treatment with Fixed Duration Venetoclax among Patients with Chronic Lymphocytic Leukemia
Dureshahwar Jawaid
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Dureshahwar Jawaid
Favorite
Jayawant, Eleanor

Brighton and Sussex Medical School
1005 - Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Eleanor Jayawant
Favorite
Jellison, Evan
1048 - SH2-Flow: A Multiplex Single Cell Phosphotyrosine Profiling Tool for B-cell Malignancies
Evan Jellison
Favorite
Jen, Min-Hua

Eli Lilly and Company
2012 - Matching-Adjusted Indirect Comparison of Pirtobrutinib vs Venetoclax Continuous Monotherapy in Patients with Relapsed/Refractory CLL Previously Treated with a Covalent BTK Inhibitor
Min-Hua Jen
Favorite
Jensen, Christopher E.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Christopher E. Jensen
Favorite
Jestrabek, Hendrik

Department I for Internal Medicine, University Hospital Cologne
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Hendrik Jestrabek
Favorite
Jiang, Qu

Department for Hematology, Cell Therapy and Hemostaseology, University Hospital of Leipzig
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Qu Jiang
Favorite
Jiang, Rui

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Rui Jiang
Favorite
1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Rui Jiang
Favorite
Jiang, Yanwen

Genentech, Inc
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Yanwen Jiang
Favorite
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Yanwen Jiang
Favorite
jiang, yi
1013 - The role of artificial intelligence in differential diagnosis and prognostic significance of Small B-cell lymphoma
yi jiang
Favorite
Jin, Hui

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1002 - m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia
Hui Jin
Favorite
1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Hui Jin
Favorite
1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Hui Jin
Favorite
Jin, Huimin
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Huimin Jin
Favorite
Johnston, Rosalynd

Brighton and Sussex University Hospital Trust
1005 - Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Rosalynd Johnston
Favorite
1023 - Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
Rosalynd Johnston
Favorite
Jondreville, Ludovic

INSERM, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Ludovic Jondreville
Favorite
Jones, John

East Sussex Healthcare NHS Trust
1005 - Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
John Jones
Favorite
Jones, Rebecca

1 Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3,10126, Torino, Italy
2 Department of Molecular Biotechnology and Health Sciences, University of Torino
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Rebecca Jones
Favorite
Jurczak, Wojciech

Maria Skłodowska-Curie National Research Institute of Oncology
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Wojciech Jurczak
Favorite
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Wojciech Jurczak
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Wojciech Jurczak
Favorite
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Wojciech Jurczak
Favorite
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Wojciech Jurczak
Favorite
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Wojciech Jurczak
Favorite
Jurkovikova, Jana

Louis Pasteur University Hospital Košice
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Jana Jurkovikova
Favorite